Men’s Health Month: Latest in Detection, Imaging and Therapy for Prostate Cancer
Prostate cancer is the second most common cancer in men behind skin cancer. For early detection, PSA (prostate-specific antigen) is an easily measured blood-borne marker that becomes elevated in patients with both benign prostate conditions and prostate cancer. PSMA (prostate specific membrane antigen) is a highly expressed marker in the membrane of prostate cancer cells that is being used for targeted radiotherapy and non-invasive patient imaging.
In this Simon Says session, urologist and surgeon Clinton Bahler, M.S., M.D., associate professor of urology at IU School of Medicine, and radiologist Mark Tann, M.D., professor of clinical radiology and imaging sciences, discuss recent developments in targeted imaging and therapy for prostate cancer, and the applications of that technology in advancing patient care. Radiopharmaceutical chemist Mark A. Green, Ph.D., professor of radiology and imaging sciences at IU School of Medicine, moderates.
